Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan

References

• Aranda-Reneo I, Oliva-Moreno J, Vilaplana-Prieto C, et al. (2013). Informal care of patients with schizophrenia. J Ment Health Policy Econ, 16, 99–108
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. (2008). The burden of schizophrenia on caregivers: A review. Pharmacoeconomics, 26, 149–62
   PubMed Web of Science ®Google Scholar
• Caqueo-Urizar A, Gutierrez-Maldonado J, Miranda-Castillo C. (2009). Quality of life in caregivers of patients with schizophrenia: A literature review. Health Qual Life Outcomes, 7, 84
   PubMed Web of Science ®Google Scholar
• Cheung S, Hamuro Y, Mahlich J, et al. (2017). Drug utilization of Japanese patients diagnosed with schizophrenia: An administrative database analysis. Clin Drug Investig, 37, 559–69
   PubMed Web of Science ®Google Scholar
• Flyckt L, Fatouros-Bergman H, Koernig T. (2015). Determinants of subjective and objective burden of informal caregiving of patients with psychotic disorders. Int J Soc Psychiatry, 61, 684–92
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. (2012). Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res, 134, 187–94
   PubMed Web of Science ®Google Scholar
• Gupta S, Isherwood G, Jones K, Van Impe K. (2015a). Assessing health status in informal schizophrenia caregivers compared with health status in non-caregivers and caregivers of other conditions. BMC Psychiatry, 15, 162
   PubMed Web of Science ®Google Scholar
• Gupta S, Isherwood G, Jones K, Van Impe K. (2015b). Productivity loss and resource utilization, and associated indirect and direct costs in individuals providing care for adults with schizophrenia in the EU5. Clinicoecon Outcomes Res, 7, 593–602
   PubMed Web of Science ®Google Scholar
• Gutierrez Maldonado J, Caqueo Urizar A, Kavanagh DJ. (2005). Burden of care and general health in families of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol, 40, 899–904
   PubMed Web of Science ®Google Scholar
• Han C, Lee B, Kim Y, et al. (2005). Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Prim Care Community Psychiatr, 10, 119–24
   Google Scholar
• Hanzawa S. (2012). Toward an effective family support system in Japan from research on family caregivers and schizophrenia patients in East Asian countries. Int J Mental Health, 41, 82–96
   Web of Science ®Google Scholar
• Hanzawa S, Bae JK, Tanaka H, et al. (2010). Caregiver burden and coping strategies for patients with schizophrenia: Comparison between Japan and Korea. Psychiatry Clin Neurosci, 64, 377–86
   PubMed Web of Science ®Google Scholar
• Jagannathan A, Thirthalli J, Hamza A, et al. (2014). Predictors of family caregiver burden in schizophrenia: Study from an in-patient tertiary care hospital in India. Asian J Psychiatr, 8, 94–8
   PubMedGoogle Scholar
• Jin H, Mosweu I. (2017). The societal cost of schizophrenia: A systematic review. Pharmacoeconomics, 35, 25–42
   PubMed Web of Science ®Google Scholar
• Lasebikan VO, Ayinde OO. (2013). Family burden in caregivers of schizophrenia patients: Prevalence and socio-demographic correlates. Indian J Psychol Med, 35, 60–5
   PubMedGoogle Scholar
• Lee H, Iijima Y, Reade C. (2011). Employee preference for performance-related pay: Predictors and consequences for organizational citizenship behaviour in a Japanese firm. Int J Hum Resour Man, 22, 2086–109
   Web of Science ®Google Scholar
• Magliano L, Fiorillo A, De Rosa C, et al. (2005a). Family burden in long-term diseases: A comparative study in schizophrenia vs physical disorders. Soc Sci Med, 61, 313–22
   PubMed Web of Science ®Google Scholar
• Magliano L, Fiorillo A, Fadden G, et al. (2005b). Effectiveness of a psychoeducational intervention for families of patients with schizophrenia: Preliminary results of a study funded by the European Commission. World Psychiatr, 4, 45–9
   PubMedGoogle Scholar
• Mahlich J, Nishi M, Saito Y. (2015). Modelling the budget impact of long acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clinicoecon Outcomes Res, 7, 267–72
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Mahlich J. (2017). Productivity and deadweight losses due to relapses of schizophrenia in Japan. Neuropsychiatr Dis Treat, 13, 1341–1348
   PubMed Web of Science ®Google Scholar
• National Federation of Mental Health and Welfare Party in Japan. (2010). Research report concerning an effective support for family in order to promote independent community life of people with mental disorders and to ensure stable life of their family. National Federation of Mental Health and Welfare Party in Japan, Tokyo
   Google Scholar
• Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D. (2008). Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: A 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy, 6, 41–53
   PubMedGoogle Scholar
• Papastavrou E, Charalambous A, Tsangari H, Karayiannis G. (2012). The burdensome and depressive experience of caring: What cancer, schizophrenia, and Alzheimer’s disease caregivers have. Cancer Nurs, 35, 187–94
   PubMed Web of Science ®Google Scholar
• Phanthunane P, Whiteford H, Vos T, Bertram M. (2012). Economic burden of schizophrenia: Empirical analyses from a survey in Thailand. J Ment Health Policy Econ, 15, 25–32
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. (1993). The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics, 4, 353–65
   PubMed Web of Science ®Google Scholar
• Sado M, Inagaki A, Koreki A, et al. (2013). The cost of schizophrenia in Japan. Neuropsychiatr Dis Treat, 9, 787–98
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, Welham J, McGrath J. (2005). A systematic review of the prevalence of schizophrenia. PLoS Med, 2, e141
   PubMed Web of Science ®Google Scholar
• Sharif F, Shaygan M, Mani A. (2012). Effect of a psycho-educational intervention for family members on caregiver burdens and psychiatric symptoms in patients with schizophrenia in Shiraz, Iran. BMC Psychiatry, 12, 48
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry, 168, 603–9
   PubMed Web of Science ®Google Scholar
• Wu E, Birnbaum H, Shi L, et al. (2005). The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry, 66, 1122–9
   PubMed Web of Science ®Google Scholar
• Zeidler J, Mahlich J, Greiner W, Heres S. (2013). Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy, 11, 509–21
   PubMedGoogle Scholar
• Zendjidjian X, Richieri R, Adida M, et al. (2012). Quality of life among caregivers of individuals with affective disorders. J Affect Disord, 136, 660–5
   PubMed Web of Science ®Google Scholar